Mehmood Khan, M.D.
Chief Executive Officer
Mehmood Khan, M.D., is Chief Executive Officer and Board Member of Life Biosciences Inc. In his role as CEO, Dr. Khan provides strategic direction and operational oversight across Life Biosciences and its six daughter companies. His vision of a more efficient and effective drug development pathway will drive innovation in the science and technology that Life Biosciences advances. By leveraging his diverse experience in pharmaceutical, clinical, and consumer industries, Dr. Khan is the ideal leader for Life Biosciences through its evolution and emergence as a global leader in longevity research and product development. Dr. Khan previously served as Global Vice Chairman and Chief Scientific Officer of PepsiCo. He played a pivotal role in the company’s global R&D efforts to create breakthrough innovations in food, beverages, and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio. Dr. Khan also oversaw their global sustainability initiatives. Prior to joining PepsiCo, Dr. Khan served as President of Global R&D at Takeda Pharmaceuticals, leading the global efforts of one of the largest pharmaceutical companies in the world by revenue. Before moving into industry, Dr. Khan had a distinguished medical career as a practicing faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. Dr. Khan is a member of the Board of Directors of Reckitt Benckiser, National Institute of Standards and Technology (NIST), and Indigo Ag. He also serves as Chair of the U.S. Council on Competitiveness. Dr. Khan earned his medical degree from the University of Liverpool Medical School, England and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians, London, a Fellow of the American College of Endocrinology, and holds two ad honorem PhD's in humanities and international law. He has been exclusively featured in numerous publications including Fast Company's 100 Most Creative People in Business.
Co-Founder, President & Chief Investment Officer
Tristan Edwards is Co-founder, President and Chief Investment Officer of Life Biosciences. He also sits on the Boards of Continuum Biosciences, Animal Biosciences, Senolytic Therapeutics and Jumpstart Fertility. Tristan brings extensive global financial capital markets, regulatory compliance, and fiduciary oversight experience to the group, following a 16-year investment career spanning leading financial organizations across Australia, London, HK, and Singapore. Having recognized the opportunity to leverage this experience in an entrepreneurial environment, he has subsequently moved to pursue his passion for helping create a scalable platform for financing and enabling the world’s best scientists and thought leaders to create change. Tristan’s professional background has been in senior investment roles at leading financial groups such as Goldman Sachs, Brevan Howard, Trafalgar Capital and Mosaic Asset Management. He started his career with the Australian Commonwealth Department of Finance. Tristan has a degree in commerce from the University of Tasmania, and held the CFA, CMT and CPA designations.
David A. Sinclair, Ph.D., A.O.
David A. Sinclair Ph.D., A.O. is Co-founder at Life Biosciences. He is a tenured professor in the Department of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for the Biology of Aging Research. Dr. Sinclair is regarded as one of the world’s leading researchers on aging and age-associated diseases, with key contributions to understanding why we age and how to slow and even reverse the process. He has co-founded multiple biotechnology and genomics companies working on aging, neurological, metabolic, infectious and rare diseases. Dr. Sinclair’s work has been featured in five books, two documentary movies, on CBS 60 Minutes, in Morgan Freeman’s “Through the Wormhole” and more. He has received more than 35 awards for his medical research, innovation, and teaching. In 2014, he was named as TIME’s “100 Most Influential People in the World”, TIME’s “50 Most Influential People in Health Care” in 2018 and was appointed an Officer of the Order of Australia. He serves on the non-profit boards of the American Federation for Aging Research and the Sanford Lorraine Cross Award.
John Amatruda, M.D.
President, Life Laboratories
Dr. John Amatruda is President of Life Laboratories, a division of Life Biosciences, and a member of Life's Scientific Advisory Board. Throughout his 26-year career in drug research and development, Dr. Amatruda has produced drugs that treat diabetes, obesity, cardiovascular disease and more. In addition to tenures as a professor at Yale University School of Medicine and The University of Rochester School of Medicine, he also co-founded the biotech company CohBar, served on numerous scientific advisory panels and Boards of Directors and was a Vice President at Bayer Corp and a Senior Vice President at Merck Pharmaceuticals. A prolific author, Dr. Amatruda has published over 150 papers, abstracts, reviews and book chapters, primarily on diabetes and cardiovascular disease. Dr. Amatruda received a BA from Yale University, an MD from the Medical College of Wisconsin and completed clinical training in medicine and fellowship in endocrinology and metabolism at the Johns Hopkins Hospital.
Amit Shashank is a strategically-oriented global leader, with more than twenty years of international experience in technology and business services organizations. As General Counsel, he oversees Life Biosciences’s government affairs, legal, and compliance initiatives. Amit is a leader in navigating complex regulatory approvals and developing global strategic alliances that span mergers and acquisitions, commercial transactions, and all phases of corporation financings. On two separate occasions, Amit has led companies toward commercializing and liquidity events which include initial public offerings (IPO). Most recently, Amit served as Executive Vice President, General Counsel and Secretary of Aricent, a global R&D engineering and design powerhouse, which under his leadership as part of the executive team, grew to over 10,000 employees. In 2018, Amit was instrumental in supporting KKR & Co. in the sale of Aricent to Altran Technologies (EPA: ALT) for $2 billion. Prior to Aricent, Amit served as Executive Vice President, General Counsel, Chief Compliance Officer, and Secretary at ExlService Holdings, Inc. (NASDAQ: EXLS), an operations management and analytics company with more than 20,000 employees globally, where he led the IPO and NASDAQ listing of the company. Amit began his career at Shearman and Sterling LLP after graduating from The University of Michigan Law School, where he was editor-in-chief of the Michigan Journal of International Law. Amit is also a Rhodes Scholar and an adjunct professor at Columbia University Law School.
Nick Ventresca is the Chief Technology Officer at Life Biosciences. Nick brings over 20 years’ experience in Information Technology (IT) for large multi-national organizations, mid-sized biopharmas and startup biotechs. Nick has broad international expertise implementing innovative scientific and patient-centric technology. Most recently, he grew strategic IT solutions for late-stage biotechs now commercializing. Previously, he served as CIO for high-profile organizations including Ariad (now Takeda), Genzyme (now Sanofi), Charles River Laboratories, Visiting Nurse Service of New York and Warner Lambert (now Pfizer), and was Chief Technology Officer for Pepsi Cola International. Nick is a graduate of Fordham University with a BS in biology and studied for two years at the La Sapienza School of Medicine in Rome, Italy.
Brian Malone, F.C.A.
Brian Malone is Chief Financial Officer at Life Biosciences. Brian brings over 35 years of experience in financial services, working with investment firms in Ireland, London and Boston. Brian was the Chief Financial Officer of Longwood Fund Management and also served as the first CFO/COO of many of the companies that Longwood incubated including some that went on to be NASDAQ listed. Most recently, he was the Senior Vice President of Finance at Axial Biotherapeutics, Inc., where he was responsible for all aspects of finance, operations, and information technology. Brian has an Honors Degree in science from University College Dublin and is a Fellow of the Irish Institute of Chartered Accountants. He recently completed a post-graduate course in strategy for pharma and biotech industries.
David Setboun, Pharm.D, M.B.A.
David Setboun brings 20 years of experience in general management and commercial for biopharma companies in Europe and Americas. Previously, he served as VP and General Manager for Biogen France. Prior to his work at Biogen, he held different senior executive positions at AstraZeneca, Eli Lilly & Sanofi. He brought to market numerous treatments and technologies across a broad range of therapeutic areas. He holds a Pharm.D from Paris XI University and an HEC MBA & Advance Management Program from Harvard Business School.
Frances Toneguzzo, Ph.D.
Head of Intellectual Property
Dr. Frances Toneguzzo is Head of Intellectual Property at Life Biosciences. Dr. Toneguzzo leads with an extensive skill set in technology evaluation, business development and licensing. Dr. Toneguzzo has a background in negotiating deals with life sciences companies, and is a strategic thinker and driver of new initiatives designed to stimulate, support and sustain innovation. Dr. Toneguzzo previously served as Executive Director at Partners Healthcare, Harvard University and Tufts University. Dr. Toneguzzo also is seasoned in the financing and management of startup companies, co-founding the biotech company Dyrnamix Inc. She received her PhD in biochemistry from McMaster University.
Sree Kant, M.B.A., M.P.H.
Head of Business Development
Sree Kant heads Business development at Life Biosciences and is focused on new scientific investments and strategic partnerships. Sree comes to Life with 18 years of varied healthcare and pharmaceutical industry experience. He previously was the head of early partnering strategy for Pfizer, working across different therapeutic areas/technologies and geographies with Academia, VCs/Banks, CROs, and other strategic partners. Sree was also a Principal at the Boston Consulting Group advising large pharma and biotech on R&D strategy as well as large M&A. He has an MBA from the Indian Institute of Management and an MPH from the Harvard School of Public Health. Sree is an invited speaker at key industry events and conferences on subjects of R&D strategy, innovative partnering models, industry-academia collaborations, early-stage technologies and investments, etc.
Michael Ringel, Ph.D., J.D.
Dr. Michael Ringel is Strategic Advisor at Life Biosciences. Dr. Ringel has 20 years of experience focused on corporate development, partnering, and R&D innovation. He is concurrently a Senior Partner and Managing Director at The Boston Consulting Group, where he is the Global Topic Leader for Research and Product Development. Dr. Ringel is a frequent contributor to industry journals and a popular public speaker, including having a TED talk on biopharma R&D partnering. Dr. Ringel has a BA in biology summa cum laude from Princeton University, a PhD in biology from Imperial College, and a JD cum laude from Harvard Law School.
Ivan Kaplan, J.D.
Ivan Kaplan is the Corporate Counsel at Life Biosciences. He’s a practicing corporate governance and securities attorney who has previously served as an associate at Wilson Sonsini Goodrich & Rosati, where he counseled clients on corporate transactions and general corporate governance matters. Prior to law school, Ivan served as a legislative staffer for two members of Congress. He holds an MBA from the University of Chicago Booth School of Business and a JD from the Northwestern University Pritzker School of Law.
Karolina Chwalek, Ph.D.
Technology Acquisition and Development Advisor, Life Biosciences and Co-Founder, Spotlight Biosciences
Dr. Karolina Chwalek has over a decade of research and business development experience. Dr. Chwalek holds an MSc in molecular biology and a PhD in regenerative medicine from the Max Plank Institute for Cell Biology, and a mini MBA from Harvard Business School. She did her postdoctoral research with Professor David Kaplan at Tufts University, Massachusetts, where she headed the Neuroengineering Group and holds an academic appointment in the Genetics Department at Harvard Medical School. She has worked at Tufts University, SQZ Biotech, and Harvard Medical School, managing strategic partnerships and commercializing new technologies. She has secured over $20M funding for research programs and is a co-founder of Spotlight Biosciences, a Life Daughter company.
Marc Ramis Castelltort, Ph.D.
Co-founder and CEO, Senolytic Therapeutics
Dr. Marc Ramis-Castelltort is Co-founder and CEO of Senolytic Therapeutics, a pharmaceutical company that develops a novel class of medicines by targeting damaged cells. He is an advisor for Life Biosciences Inc. in Europe helping to scout novel aging-associated ventures. Dr. Ramis-Castelltort's experience spans academia and the business world. He has had an impressive and wide-ranging career, from co-founding and leading pharmaceutical, academic, and venture capital firms, such as Senolytic Therapeutics, Cebiotex and Chasing Science, to working with premier research institutions such as Cancer Research UK, Oxford University Innovation and IRB Barcelona. The companies he’s built and advised have created drug-delivery nano-systems for cancer, brokered corporate-academic partnerships, and more. Dr. Ramis-Castelltort’s academic degrees include a PhD in biochemistry from the University of Oxford, a Harvard Business School PLD Program, an MS in chemical engineering and a BS in chemistry from IQS in Barcelona.
Doug Korn, M.B.A.
CEO, Animal Biosciences
Doug Korn is the CEO of Animal Biosciences. He most recently served as Vice President of Strategy for Mars Petcare North America where he helped lead the $4B North American division of the world’s largest pet care company, with over 3,500 associates and 20 manufacturing locations. During his seven years at Mars, the business achieved record performance with sustainable growth, improved earnings, and market share growth. Doug was directly responsible for the company’s strategic plan, corporate and portfolio strategy and business development. Prior to his time at Mars, he worked in sales and marketing at The Clorox Company and Procter & Gamble. He holds a BS in chemical engineering from Lafayette College, a MBA from Boston College, and a ThM from Liberty University.
Simon Tucker, Ph.D.
CEO, Jumpstart Fertility and Continuum Biosciences
Dr. Simon Tucker brings decades of experience in pharmaceutical research and development and management as CEO of both Jumpstart Fertility Inc. and Continuum Biosciences Inc. He previously worked at GD Searle, USA, helping make key discoveries leading to the development of a treatment for HIV infection. He was later Vice President of Research at Biota Pharmaceuticals (now Vaxart), where he was responsible for their entire intellectual property and research portfolio. In 2015, he founded and was CEO of the successful contract research organization, 360biolabs. Dr. Tucker has a BS in biochemistry from the University of Sussex and a PhD from the University of Reading.
Chair of the Technology Advisory Board
Raymond Pawlicki is Chair of the Technology Advisory Board at Life Biosciences where he is creating a world-class, next generation technology platform. Formerly the Chief Information Officer at Biogen, Ray was instrumental in transforming IT, pivotal to the company’s success. Prior to Biogen, he worked for eight years at Novartis Pharmaceuticals, A.G., serving as both CIO of the U.S. affiliate and Global CIO of the Switzerland-based, $27 billion enterprise. Ray is a Director and Member of Finance Committee for Harvard Pilgrim, one of the nation’s leading health services companies that serves 2.7 million members, and is Chairman of the IT Subcommittee of the Board of Trustees for UMass Memorial Healthcare. Ray has a BS in computer science from Montclair State University.
Lawrence Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a specialized global investment fund focused exclusively in life sciences. With 18 years of experience in investing and banking, Lawrence has expertise in all areas of investment management and deep roots in the scientific and biotech communities. Prior to Scientia Lawrence was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over AU$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained corporate finance experience advising life science companies at Deloitte. Lawrence currently serves as a Director on the Board of Nohla Therapeutics, Prana Biotechnology (NASDAQ: PRAN) and Ausbiotech, Australia’s biotechnology industry association. He holds a BS with Honors in immunology from the University of Melbourne.
Nir Barzilai, M.D.
Chief Medical Advisor
Dr. Nir Barzilai is the Chief Medical Advisor at Life Biosciences and a member of the Board of Selphagy Therapeutics. Dr. Barzilai also serves as director of the Institute for Aging Research at the Albert Einstein College of Medicine. In addition, he is a founder and board member of CohBar Inc. Listed on the Russel 2000 Index, it develops therapeutics based on mitochondrial derived peptides. He is a renowned expert and scientist in the study of the biology and genetics of aging. He is leading the TAME (Targeting Aging with MEtformin) a multi-central study to show that aging can be a target in humans in support of changing the FDA indication that is relevant to targeting aging. Dr. Barzilai is the recipient of many awards including the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity Award. His work has been profiled by outlets such as the New York Times, BBC, PBS and National Geographic. He received his MD from Technion-Israel Institute of Technology, and his work has been profiled by outlets such as the New York Times, BBC, PBS, and National Geographic.
Lindsay Wu, Ph.D.
Chief Scientific Advisor, Life Biosciences and Co-founder, Jumpstart Fertility
Dr. Lindsay Wu is Chief Scientific Advisor at Life Biosciences and Co-founder of Jumpstart Fertility. He also leads the Laboratory for Ageing Research at the University of New South Wales in Sydney, where he is developing new therapies to treat diseases of aging, such as female infertility. He sees this as an under-appreciated goal, which could help to relieve women of the societal pressures of having children at a young age. One of the companies he recruited for Life (and co-founded)—Jumpstart Fertility—is based on work done in his lab. As a prominent figure in the field of treating aging, Dr. Wu has been featured in the media many times, and is the founding organizer of the Australian Biology of Aging Conference series. He holds a RD Wright Biomedical Fellowship from the National Health and Medical Research Council of Australia, and was a Visiting Fellow at Harvard Medical School.
Jennifer Cermak, Ph.D.
SVP, Clinical Development
Dr. Jennifer Cermak is Senior Vice President of Clinical Development for Life Biosciences. A seasoned leader in the research and development of drugs and medical devices, Dr. Cermak has two decades of related experience. Having co-founded and managed multiple biotechnology startup companies, Dr. Cermak has successfully led every aspect of the production of life-changing pharmaceuticals from start to finish, and brought them to market. She holds a PhD in pathology from Boston University School of Medicine and she completed her postdoctoral fellowship in the Department of Surgery at Harvard Medical School.
Phil Lambert, Ph.D.
SVP, Discovery and Laboratories
Dr. Phil Lambert is Senior Vice President for Discovery and Laboratories at Life Biosciences. With over 25 years of experience in drug discovery and development, he brings expertise in building companies and providing efficient and predictive preclinical drug discovery to his role at Life. Prior, Dr. Lambert co-founded and was Chief Scientific Officer at VivoPath, a contract research organization providing drug discovery support to the pharmaceutical community. He also worked at an array of research institutes and pharmaceutical companies including Parke Davis and GSK. Dr. Lambert received his PhD in neuropharmacology from Imperial College, University of London and was a faculty member in the Department of Psychiatry at Emory University School of Medicine.
Michel Wathier, Ph.D.
Vice President, CMC
Dr. Michel Wathier is Vice President of Chemistry Manufacturing and Control (CMC) at Life Biosciences. With more than 20 years of experience leading the formulation development and manufacturing of complex drugs, Dr. Wathier has a deep understanding and expertise in CMC program management, operation, and regulatory. His experiences encompass devices, small and large molecules, combination products, and new modalities. Dr. Wathier has experience with regulatory environments in both the United States and internationally and has led 15 compounds through successful IND filings; he co-authored 20 patents and effectively moved numerous products from R&D to human clinical studies. His development work on devices led to Adherus and OcuSeal and their successful commercialization and acquisition in US and Europe. Dr. Wathier has a Ph.D. in organic chemistry from Avignon University, France and completed his postdoctoral fellowship at Duke University working on biomaterials in the department of chemistry.
William Avery, Ph.D., J.D., M.B.A., DABT
Vice President of Research and Development
Dr. William Avery is Vice President of Research and Development, with a focus on pre-clinical and translational activities. He joined Life Biosciences in 2017, after an extensive biotech career that included Momenta Pharmaceuticals, CombinatoRx, Millennium Pharmaceuticals, and laboratory research at Dana Farber. For over 18 years, Dr. Avery has successfully developed drugs and executed pharmacological and toxicological studies to support a range of compounds in various stages of their development. He has published 26 papers in prestigious, peer-reviewed journals. At Life Biosciences, Dr. Avery is supporting the research of our Daughter companies through proof of concept, while also playing a key role in potential licensing opportunities of Intellectual Property–from corporations and academia–that can advance the Company’s research into age-related decline. Additionally, Dr. Avery is playing a leadership role in the creation of business plans and the securing of funding. He holds a PhD in health sciences from Trident University; a JD and MBA from Suffolk University, and an M.Sc. in Clinical Investigation from Harvard.
Manuel Serrano, Ph.D.
Co-Founder and Chief Scientific Advisor, Senolytic Therapeutics
Dr. Manuel Serrano is Co-founder and Chief Scientific Advisor for Senolytic Therapeutics. He is an internationally-recognized scientist who has made significant contributions to cancer and aging research. He currently works in the Institute for Research Biomedicine in Barcelona, where he conducts award-winning work around cellular senescence and reprogramming and how they relate to degenerative diseases with a focus on lung, kidney and heart. Dr. Serrano obtained his PhD in 1991 from the University of Madrid, and conducted research in Cold Spring Harbor Laboratory in New York, where he made some important discoveries concerning p16 with implications for cancer prevention and aging. He then led research groups in Spain at the National Center of Biotechnology and the Spanish National Cancer Research Center.
Ana Maria Cuervo, M.D., Ph.D.
Co-Founder, Selphagy Therapeutics
Dr. Ana Maria Cuervo is Co-founder of Selphagy Therapeutics. She's also a professor and co-director of the Institute of Aging Studies at the Albert Einstein College of Medicine, where her group studies the role of autophagy in aging and age-related diseases. She has received prestigious awards such as the P. Bensley Award in cellular biology, Vincent Cristofalo Award in Aging, the Saul Koreyin Translational Medicine and the LaDonne Schulman Teaching Award. Dr. Cuervo is an elected member of the American Academy of Arts and Sciences and of the Spanish Real Academia de Ciencias Exactas, Fisicas y Naturales. She has an MD and a PhD in biochemistry and molecular biology from the University of Valencia and received postdoctoral training at Tufts University. She is also a member of the prestigious National Academy of Sciences.
Evripidis Gavathiotis, Ph.D.
Co-Founder and Chief Scientific Advisor, Selphagy Therapeutics
Dr. Evripidis Gavathiotis is Co-founder and Chief Scientific Advisor for Selphagy Therapeutics. Dr. Gavathiotis is also an Associate Professor of Biochemistry and Medicine at Albert Einstein College of Medicine and a faculty member at the Institute for Aging Research, the Gottesman Institute for Stem Cell Biology and Regenerative Medicine, and other institutions. He is conducting innovative research on the role of proteins in cancer and other age-associated diseases, with the goal of developing new medicines through small molecule modulators. Dr. Gavathiotis has co-authored over 50 scientific publications and 15 United States patent applications, and received numerous awards throughout his career, including the 2014 Young Chemical Biologist Award, the Irma T. Hirschl Career Scientist Award and the Pershing Square Sohn Prize. He trained at Rockefeller University and the Dana-Farber Cancer Institute, and received his PhD from the University of Nottingham.
Kyle Hoehn, Ph.D.
Co-Founder, Continuum Biosciences
Dr. Kyle Hoehn is Co-founder of Continuum Biosciences. Dr. Hoehn is a metabolic biochemist and physiologist conducting cutting-edge research on obesity and its related disorders including diabetes and obesity-related cancers. His work is focused on altering metabolism to treat disease and delay aging. Dr. Hoehn received a Ph.D. in biochemistry from Colorado State University and completed postdoctoral training at the Garvan Institute of Medical Research in Sydney. Dr. Hoehn is currently the Chief Scientific Advisor at Continuum Biosciences and holds professorship appointments at both the University of New South Wales and the University of Virginia.
Webster Santos, Ph.D.
Co-Founder, Continuum Biosciences
Webster Santos is Co-founder of Continuum Biosciences, and is currently the Cliff and Agnes Lilly professor of Chemistry at Virginia Tech. As the inventor of over 13 patents, his research efforts include designing inhibitors of RNA involved in HIV-1, sphingosine kinase inhibitors, mitochondrial uncouplers and developing synthetic chemistry methods involving boron and silicon. He serves on the editorial boards of Medicinal Research Reviews and Current Topics in Medicinal Chemistry, and is the recipient of numerous awards, including the Innovators Award and an endowed Blackwood Faculty Fellowship at Virginia Tech. He received his B.S. and Ph.D. at the University of Virginia, which was followed by an NIH postdoctoral fellowship in the department of chemistry and chemical biology at Harvard University.
Hayden Homer, M.D., Ph.D.
Co-Founder, Jumpstart Fertility
Dr. Hayden Homer is Co-founder of Jumpstart Fertility. As the director of Queensland’s first research laboratory dedicated to understanding the molecular control of egg development, he brings vast experience in the field of fertility research to his role. His research seeks to develop innovative interventions for reversing poor egg quality, the most challenging fertility problem that, at present, can only be circumvented using better quality eggs donated by other women. Dr. Homer's findings have been published in premier journals including Science, Genes & Development, Developmental Cell and Nature Cell Biology, and he has won over a dozen highly prestigious prizes and awards. He is a practicing fertility specialist, is an accredited Reproductive Endocrinology and Infertility sub-specialist with both the Australian & New Zealand and the British Royal Colleges of O&G and holds a PhD in egg biology research from the UK.
Adam Neumann is the founding investor of Life Biosciences and sits on the board of directors. He is also the CEO of WeWork, the global shared-office-space company with locations in 40 cities and 18 countries. Adam has deep experience creating successful companies, and a passion for building connected and purpose-driven corporate cultures. Prior to WeWork, Adam co-founded the co-working space Green Desk, which helped to transform Brooklyn's DUMBO neighborhood into a hub for small, creative companies, and Big Tent Inc., which develops children’s clothing.
David Sinclair, Ph.D., A.O.
David Sinclair Ph.D., A.O. is Co-founder at Life Biosciences. He is a tenured professor in the Department of Genetics at Harvard Medical School and Co-Director of the Paul F. Glenn Center for the Biological Mechanisms of Aging. Dr. Sinclair is regarded as one of the world’s leading researchers on aging and age-associated diseases, with key contributions to understanding why we age and how to slow and even reverse the process. He has co-founded multiple biotechnology and genomics companies working on aging, neurological, metabolic, infectious and rare diseases. Dr. Sinclair’s work has been featured in five books, two documentary movies, on CBS 60 Minutes, in Morgan Freeman’s “Through the Wormhole” and more. He has received more than 35 awards for his medical research, innovation, and teaching. In 2014, he was named as TIME’s “100 Most Influential People in the World” and in 2018 was appointed an Officer of the Order of Australia. He serves on the non-profit boards of the American Federation for Aging Research and the Sanford Lorraine Cross Award.
Mehmood Khan, M.D.
CEO & Member of the Board
Mehmood Khan, M.D., is Chief Executive Officer and Board Member of Life Biosciences Inc. In his role as CEO, Dr. Khan provides strategic direction and operational oversight across Life Biosciences and its six daughter companies. His vision of a more efficient and effective drug development pathway will drive innovation in the science and technology Life Biosciences advances. By leveraging his diverse experience in pharmaceutical, clinical, and consumer industries, Dr. Khan is the ideal leader for Life Biosciences through its evolution and emergence as a global leader in longevity research and product development. Dr. Khan previously served as Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, a Fortune 50 company employing upwards of 250,000 employees across 22 brands. At PepsiCo, Dr. Khan played a pivotal role in the company’s global R&D efforts to create breakthrough innovations in food, beverages, and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio. Dr. Khan also oversaw PepsiCo's global sustainability initiatives based on the belief that success in business is inextricably linked to the sustainability of the world we share. Prior to joining PepsiCo, Dr. Khan served as President of Global R&D at Takeda Pharmaceuticals, leading the global efforts of one of the largest pharmaceutical companies in the world by revenue. Before moving into industry, Dr. Khan had a distinguished medical career as a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also spent nine years leading programs in diabetes, endocrinology, metabolism and nutrition for the Hennepin County Medical Center in Minneapolis. Dr. Khan is a member of the Board of Directors of Reckitt Benckiser, Indigo Ag, the Foundation for Food and Agricultural Research at the U.S. Department of Agriculture. He also serves as Chair of the U.S. Pakistan Business Council and Chair, U.S. Council on Competitiveness in Washington DC.
Dr. Khan earned his medical degree from the University of Liverpool Medical School, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians, London, and a Fellow of the American College of Endocrinology.
Bracken Darrell, M.B.A.
Board of Directors
Bracken Darrell is Chief Executive Officer at Logitech, where he brings more than twenty years of experience in business and brand management in successful global consumer companies, including Whirlpool, Procter & Gamble and General Electric. His broad executive management experience has spanned manufacturing, supply chain, product innovation, consumer services and marketing—targeting customers in mature and emerging markets. He has led growth and reinvention for iconic brands such as Old Spice, Braun, and Logitech. Bracken's prior roles included President of Braun within Procter & Gamble. He spent 12 years at Procter & Gamble in executive management positions as well as earlier years in brand management and five years at GE in general management roles. Bracken began his career with Arthur Anderson and then PepsiCo. Bracken holds an MBA degree from Harvard Business School and a BA degree in English from Hendrix College in Arkansas.